{
    "clinical_study": {
        "@rank": "125947", 
        "arm_group": [
            {
                "arm_group_label": "trivalent rotavirus genetic reassortment vaccine", 
                "arm_group_type": "Experimental", 
                "description": "2ml of rotavirus genetic reassortment vaccine by mouth every month for three month"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2ml of placebo by mouth every month for three month"
            }
        ], 
        "brief_summary": {
            "textblock": "Assessment and evaluation the rotavirus gastroenteritis prevention effect and severe\n      rotavirus diarrhea reducing effectiveness of human body, which inoculate trivalent rotavirus\n      genetic reassortment vaccine."
        }, 
        "brief_title": "Phase Three Clinical Trials of Trivalent Rotavirus Genetic Reassortment Vaccine", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Randomized", 
            "Double-blind", 
            "Placebo Control Design"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  6 to 13 weeks aged healthy baby;\n\n          -  Guardian volunteer to participate in the study and sign informed consent;\n\n          -  have use thermometer as required and the ability to fill in the diary table;\n\n          -  Subjects guardian can abide by the requirements of clinical research scheme;\n\n          -  The past has not been vaccinated rotavirus vaccine;\n\n          -  Normal term eutocia, birth weight up to standard;\n\n          -  Axillary temperature is 37.0 \u2103 or less.\n\n        Exclusion Criteria:\n\n          -  With allergy, convulsion, epilepsy, encephalopathy and spirit history or the family\n             history;\n\n          -  Be allergy to any ingredients in the vaccine;\n\n          -  Known immunology function damage or low person;\n\n          -  Immunosuppressant therapy Accepter;\n\n          -  Suffering from congenital malformation and developmental disorder;\n\n          -  Known or suspected also suffer from diseases including: digestive system disease,\n             respiratory system disease, acute infection, mother or I have HIV infection,\n             cardiovascular diseases, malignant tumor during treatment, skin disease;\n\n          -  Inoculation other vaccine within 7 days."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "13 Weeks", 
            "minimum_age": "6 Weeks"
        }, 
        "enrollment": {
            "#text": "10020", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01738074", 
            "org_study_id": "HNCDC-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "trivalent rotavirus genetic reassortment vaccine", 
                "intervention_name": "trivalent rotavirus genetic reassortment vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "rotavirus", 
            "trivalent genetic reassortment vaccine", 
            "Phase three clinical trials"
        ], 
        "lastchanged_date": "November 28, 2012", 
        "number_of_arms": "2", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Antibody titer differences in serum", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks after full vaccination"
            }, 
            {
                "measure": "Incidence differences of rotavirus diarrhea", 
                "safety_issue": "Yes", 
                "time_frame": "2 years after full vaccination."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01738074"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Center for Disease Control and Prevention, Henan Province", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Center for Disease Control and Prevention, Henan Province", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}